



Expert Opinion on Investigational Drugs

ISSN: 1354-3784 (Print) 1744-7658 (Online) Journal homepage: informahealthcare.com/journals/ieid20

Erratum

To cite this article: (2009) Erratum, Expert Opinion on Investigational Drugs, 18:6, 873-873, DOI: <u>10.1517/13543780903035108</u>

To link to this article: https://doi.org/10.1517/13543780903035108



Published online: 25 May 2009.

Submit your article to this journal \square

Article views: 241



View related articles 🗹

In the Drug Evaluation "Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor" by Gimsing P, published in the April 2009 issue of Expert Opinion on Investigational Drugs (*Expert Opin. Investig. Drugs* (2009) 18(4):501-508), the declaration of interest statement on page 507 should have read as follows:

P Gimsing was a consultant for TopoTarget when the Phase I and II trials on malignant hematological diseases were planned 3 years ago and was the principal investigator of these trials, but has had no such position since then and no other connections.

The author, editors and publisher sincerely regret any inconvenience that these omissions may have caused.

Convitight O 2009 Informa UN Lited Convitight O 2009 Information Distribution Convitight Or Commencial Distribution Convitight Or Commencial Strate convictor resonance Not for sale or promitical Authorized Users convictor resonance Not for sale user promitical Authorized Users convictor resonance Not for sale user promitical Authorized Users convictor resonance Not for sale user promitical Authorized Users convictor resonance Not for sale user promitical Authorized Users convictor resonance Not for sale user promitical Authorized Users convictor resonance Not for sale user and prima a single convictor resonance Not for sale user and prima a single convictor resonance Not for sale users and prima a singl